United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 3,000 shares of the company's stock, valued at approximately $449,000.
Several other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after purchasing an additional 92,014 shares in the last quarter. Amundi grew its stake in shares of DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after acquiring an additional 240,126 shares during the last quarter. KBC Group NV boosted its stake in DaVita by 0.8% in the 4th quarter. KBC Group NV now owns 316,155 shares of the company's stock worth $47,281,000 after purchasing an additional 2,636 shares in the last quarter. BNP Paribas Financial Markets grew its position in DaVita by 23.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company's stock valued at $47,874,000 after purchasing an additional 56,389 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in DaVita by 4.9% during the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock valued at $39,712,000 after purchasing an additional 12,339 shares in the last quarter. Institutional investors own 90.12% of the company's stock.
Analyst Ratings Changes
Several research firms have recently weighed in on DVA. Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. StockNews.com cut shares of DaVita from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Finally, Cowen restated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, DaVita presently has an average rating of "Hold" and an average price target of $166.33.
Check Out Our Latest Stock Report on DVA
DaVita Price Performance
Shares of NYSE:DVA opened at $153.18 on Tuesday. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The stock has a market capitalization of $12.25 billion, a PE ratio of 14.26, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The firm's 50 day moving average price is $157.13 and its 200-day moving average price is $157.52. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60.
DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Equities research analysts expect that DaVita Inc. will post 10.76 EPS for the current year.
DaVita Company Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
